This corresponds to what is known from successful randomized trials of reducing CAD risk with statin treatment,33 PCSK9 inhibitors34 and ezetimibe,29 and unsuccessful trials of CETP inhibitors.35 The gene discussed is PCSK9; the disease is coronary artery disorder.